| Name | Title | Contact Details |
|---|
Cerebros Medical Systems is a Scranton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infusion Systems is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Established in 1946, OMRF is an independent, nonprofit biomedical research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders, and diseases of aging. Breakthroughs in our labs have led to three FDA-approved drugs, including the first targeted therapy approved in the U.S. for sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. OMRF`s critical research is helping people live longer, healthier lives, one discovery at a time. Along the way, OMRF has garnered worldwide media attention, from leading scientific publications like The New England Journal of Medicine and Science to The New York Times and The Wall Street Journal. By pushing the boundaries of biomedical science, our researchers are helping to win the war against human disease, one discovery at a time.
Radicle Health offers cannabis curriculum packages and modules for nurses, other healthcare professionals, and cannabis students at a range of price points.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.